The expression and prognostic value of stem cell markers Bmi-1, HESC5:3, and HES77 in human papillomavirus-positive and -negative oropharyngeal squamous cell carcinoma by Mohamed, Hesham et al.
Original Article
Tumor Biology
March 2019: 1–10
 The Author(s) 2019
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/1010428319840473
journals.sagepub.com/home/tub
The expression and prognostic value of
stem cell markers Bmi-1, HESC5:3,
and HES77 in human papillomavirus–
positive and –negative oropharyngeal
squamous cell carcinoma
Hesham Mohamed1,2 , Jaana Hagstro¨m1,3*, Lauri Jouhi4*, Timo Atula4,
Alhadi Almangush1, Antti Ma¨kitie4,5,6# and Caj Haglund3,7#
Abstract
Human papillomavirus is detected in over 50% of oropharyngeal squamous cell carcinomas. Human papillomavirus–
positive oropharyngeal squamous cell carcinomas differ from human papillomavirus–negative tumors, and both expression
patterns are classified as distinct entities. The Bmi-1 oncogene is a well-known member of the mammalian polycomb-
group family. HESC5:3 and HES77 are newly developed monoclonal antibodies produced against undifferentiated embryo-
nic stem cells. Our aim was to explore their roles in both human papillomavirus–positive and –negative oropharyngeal
squamous cell carcinomas. Our cohort comprised 202 consecutive oropharyngeal squamous cell carcinoma patients diag-
nosed and treated with curative intent. We used tissue microarray tumor blocks to study the immunohistochemical
expression of Bmi-1, HESC5:3, and HES77. We compared the expressions of these stem cell markers with p16 immu-
noexpression and human papillomavirus status, as well as with other characteristics of the tumor, and with patients’ clini-
cal data and follow-up data. Human papillomavirus– and p16-positive tumors expressed less Bmi-1 and more HESC5:3
than the negative tumors. HES77 expression was high in human papillomavirus–positive oropharyngeal squamous cell car-
cinoma, but it did not correlate with p16 positivity. In our multivariable model, Bmi-1 and HESC5:3 were still associated
with human papillomavirus, but the association between human papillomavirus and HES77 remained absent. In conclusion,
Bmi-1, HESC5:3, and HES77 may have a different role in human papillomavirus–positive and human papillomavirus–
negative tumors. There was no correlation between Bmi-1, HESC5:3, and HES77 expression and survival.
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Introduction
Oropharyngeal squamous cell carcinoma (OPSCC) is
the 12th most common cancer worldwide.1 Tobacco
and alcohol consumption is a traditional risk factor for
OPSCC.2 Lately, the infection with high-risk types of
human papillomavirus (HPV), particularly HPV-16,
has been identified as an important cause of OPSCC.3
HPV positivity is detected in 52% of tonsillar carcino-
mas in the UK,4 in more than 60% of OPSCCs cases in
the USA,5 and in more than 50% in some European
countries.6,7 According to the latest World Health
Organization (WHO) classification of head and neck
tumors, HPV-positive and HPV-negative head and
neck tumors represent different entities.8 They behave
differently, as HPV-positive head and neck squamous
cell carcinomas (HNSCC) associate less with smoking
and alcohol use, have a higher radiosensitivity, and
have a better prognosis than HPV-negative tumors.9,10
The main treatment approaches for OPSCC are surgery
and radiotherapy, either separately or in combination.
Definitive chemoradiotherapy is used for advanced
stage disease.11 Still, OPSCC mortality remains quite
high, and the 5-year overall survival (OS) does not
exceed 60%.12,13
The p16 gene is a well-known tumor suppressor,
identified in 1993 as cyclin-dependent kinase inhibitor
(CDKI),14 which is encoded by a gene localized on
chromosome 9p21.15 Subsequently, in 1994, its tumori-
genic role was confirmed for many types of cancers.15,16
p16 expression associates positively with the presence
of HPV16 in OPSCC cancers.17,18 In addition, it has a
positive prognostic value in OPSCC.18,19
Epithelial–mesenchymal transition (EMT) appears
to play an important role in tumor metastasis. In EMT,
epithelial cells lose their cell polarity and cell-to-cell
adhesion and gain migratory and invasive properties as
they become more like mesenchymal-type cancer stem
cells (CSCs). These cells are thought to express specific
proteins named CSC markers.20 The properties and
behavior of CSCs may explain the tumor recurrence
following curative treatment. Moreover, a recent study
has found that HPV promotes keratinocyte stem cells
to become CSCs, which may be the cause of increased
metastasis rate of HPV-related tumors.21
The B cell-specific Murine leukemia virus Integration
site 1 (Bmi-1) oncogene is a well-known member of the
mammalian polycomb-group family. It plays a signifi-
cant role in self-renewal and repair in normal adult stem
cells,22 and it also participates in preventing cellular
senescence and immortalization through activation of
telomerase.22 Bmi-1 is considered to act as an onco-
gene.23 Jacobs et al.23 showed that in Bmi-1-negative
cells, p16ink expression appears to be upregulated, and
the in vivo and in vitro results showed that Bmi-1 upre-
gulation downregulates p16ink. Furthermore, in
leukemia, the overexpression of the Bmi-1 oncogene
was found to play a role in leukemic stem cell prolifera-
tion and maintenance.24 Moreover, in breast cancer,
Bmi-1 appears to play a role in tumor progression and
lymph node metastasis.25 A recent study by our group
reported a significant prognostic value of Bmi-1 expres-
sion in tongue squamous cell carcinoma.26
HESC5:3 is a novel monoclonal antibody raised
against undifferentiated embryonic stem cells, although
its antigen epitope has not yet been determined.27
HESC5:3 was previously found to distinguish between
neoplastic and non-neoplastic follicular thyroid
nodules.27 HES77 is another newly developed monoclo-
nal antibody with an undetermined antigen epitope. Its
target antigen is located on the cell membrane.28 It is
highly specific to undifferentiated human embryonic stem
cells, but it loses its expression once the cells begin to dif-
ferentiate.28 In rectal neuroendocrine tumors, HES77
overexpression associates with a poor prognosis.28
Finding novel molecular markers could improve our
understanding of the behavior of OPSCC and help to
predict its response to different treatment modalities. In
this study, we evaluated the expression and prognostic
value of stem cell–associated markers Bmi-1, HESC5:3,
and HES77, and their association with HPV and p16
status, in a cohort of 202 consecutive OPSCC patients
treated with curative intent at the Helsinki University
Hospital.
Materials and methods
Patient selection
We identified a total of 331 patients diagnosed with
oropharyngeal cancer at the Department of
Otorhinolaryngology—Head and Neck Surgery,
Helsinki University Hospital (Helsinki, Finland)
between 1 January 2000 and 31 December 2009. We
excluded patients receiving palliative treatment
(n=44), those with concurrent (n=5) or previously
treated HNSCC (n=11), those with histology other
than SCC or a subtype of SCC (n=18), and patients
for whom no tumor tissue was available (n=51). Our
final study cohort consisted of 202 patients treated with
a curative intent; 130 patients underwent primary sur-
gery, 116 of whom received post-operative oncological
treatment. Definitive oncological treatment was admi-
nistered to 72 patients, 11 of whom required salvage
surgeries for residual disease.
Data source from hospital records
Clinical data were collected from patient records. The
median follow-up time for patients was 5 years, and all
patients had a minimum follow-up of 3 years or until
death. The dates and causes of death were obtained
2 Tumor Biology
from Statistics Finland. The patient data are described
in detail in our previous publication.29 Formalin-fixed
and paraffin-embedded surgical tissue samples were
collected from the archives of the Department of
Pathology. All slides were re-evaluated by an experi-
enced pathologist, and the cancer areas were marked
on these slides.
Tissue microarray blocks
Tissue microarray (TMA) blocks were prepared from
the donor paraffin blocks. From the selected cancer
areas, four tumors spots were detached for each case
by a 1-mm needle and placed onto a recipient paraffin
block with a semi-automatic tissue microarrayer
(Beecher Instruments, Silver Spring, MD, USA).30
Immunohistochemistry
From the TMA blocks, 4-mm thick sections were cut,
deparaffinized in xylene and rehydrated through a
graded alcohol series. Antigen retrieval was achieved by
heating the samples in 98C Tris-HCl buffer (pH 8.5)
for 20min in a pretreatment PT module (Lab Vision
Corp., Fremont, CA, USA). The samples were then
cooled to room temperature. Endogenous peroxidase
was inactivated by incubating the specimens in metha-
nol containing 1.6% hydrogen peroxidase for 30min.
The samples were treated with horse serum to block
non-specific binding sites. The staining was performed
with Dako Real Detection System, peroxidase DAB+,
in an Autostainer 480 (Lab Vision Corp).
We used a specific primary antibody for each mar-
ker: monoclonal Bmi-1 diluted 1:400 (ab 14389;
Figure 1. Immunohistochemical staining pattern of Bmi-1, HESC5:3, and HES77 in oropharyngeal carcinoma (OPSCC): (a) OPSCC
with negative Bmi-1 expression (magnification 340), (b) OPSCC with positive nuclear Bmi-1 expression (magnification 340),
(c) OPSCC with negative HESC5:3 expression (magnification 340), (d) OPSCC with positive cytoplasmic HESC5:3 expression
‘‘green arrows’’ and nuclear HESC5:3 expression ‘‘red arrows’’ (magnification 340), (e) OPSCC with negative HES77 expression
(magnification 340), and (f) OPSCC with positive cytoplasmic HES77 expression (magnification 340).
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Abcam, Cambridge, UK) incubated for 1 h,26 HESC5:3
mAb diluted 1:300 incubated for 1 h,27 and HES77
mAb diluted 1:300 incubated for 1 h.28
For Bmi-1, we used breast cancer and colon cancer
tissue samples as positive controls. For HESC5:3 and
HES77, we used colon cancer tissue as positive control.
For each staining, the negative control was a slide with-
out a primary antibody.
HPV in situ hybridization and p16 immunostaining
HPV in situ hybridization and p16 immunohistochem-
ical staining are described in detail in our previous
study by Jouhi et al. Briefly, 52% (105/202) of the
tumors were HPV-positive and 48% (97/202) were
HPV-negative, whereas 58% (117/202) of the tumors
were p16-positive and 42% (85/202) were p16-
negative.29
Scoring
Two independent investigators (H.M. and A.A.) scored
the immunopositivity of the tumor cells, and their scor-
ings were re-evaluated by a head and neck pathologist
(J.H.). In the case of a discrepancy, a consensus score
was used for further analysis.
For Bmi-1, the scoring was performed as described
by Ha¨yry et al.26 The staining was nuclear, and the per-
centage of positive tumor cells was evaluated. No posi-
tivity was graded as 0; up to 30% positive cells was
scored as 1 (very low); 30–50% as 2 (low); 50–80% as 3
(moderate); and over 80% as 4 (high).
For HESC5:3, immunopositivity was scored accord-
ing to Heikkila¨ et al.27 as follows: cytoplasmic staining
as 0 (negative), 1 (mild), 2 (moderate), and 3 (strong)
according to the intensity. The nuclear scoring was
Table 1. Expression of Bmi-1, HESC5:3, and HES77 in
oropharyngeal squamous cell carcinoma (n = 202).
Marker Positive Negative Total % positivity
Bmi-1 123 79 202 61
Cytoplasmic HESC5:3 136 66 202 67
Nuclear HESC5:3 6 196 202 3
HES77 88 114 202 44
Table 2. Expression of Bmi-1, HESC5:3, and HES77 and their association with HPV and p16 in oropharyngeal squamous cell
carcinoma (n = 202).
Variable HPV positivity P16 positivity
HPV+ HPV– All P P16+ P16– All P
Bmi-1
0 52 27 79 54 25 79
1 22 29 51 27 24 51
2 15 16 31 17 14 31
3 10 13 23 13 10 23
4 6 12 18 6 12 18
Total 105 97 202 0.006a 117 85 202 0.013a
Cytoplasmic HESC5:3
0 30 36 66 32 34 66
1 26 32 58 31 27 58
2 33 23 56 37 19 56
3 16 6 22 17 5 22
Total 105 97 202 0.016a 117 85 202 0.006a
Nuclear HESC5:3
0 101 95 196 112 84 196
1 1 2 3 2 1 3
2 1 0 1 1 0 1
3 2 0 2 2 0 2
Total 105 97 202 0.247b 117 85 202 0.183b
HES77
0 52 62 114 61 53 114
1 28 25 53 31 22 53
2 12 3 15 11 4 15
3 11 4 15 11 4 15
4 2 3 5 3 2 5
Total 105 97 202 0.030a 117 85 202 0.094a
HPV: human papillomavirus.
aChi-squared test with asymptotic P-value.
bChi-squared test with exact P-value.
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based on the percentage of positive tumor cells as fol-
lows: 0=negative, 1= low (1–35%), 2=medium (36–
75%), and 3=high (.75%).
For HES77, the scoring was performed according
Jernman et al.28 based on the intensity of the cyto-
plasmic staining. Scores ranged from 0 to 4: 0=nega-
tive expression, 1=weak expression, 2=moderate
expression, 3= strong expression, 4=very strong
expression. No nuclear HES77 positivity was detected
in this study.
For all markers, the highest score of the four spots
from each sample was used for further analysis.
Statistical analysis
We used SPSS version 20.0 (SPSS Inc., Chicago, IL,
USA) to analyze all data. The scoring results for the dif-
ferent markers were compared with clinical and patholo-
gical data. We used the chi-squared test to analyze the
categorical variables with asymptotic and exact P-values
when most suitable. We examined the relationship
between the markers and patients’ age using the
Kruskal–Wallis test. Logistic regression was used to
explore which variables were independently associated
with HPV. The Kaplan–Meier estimate with long-rank
test was used to calculate the 5-year disease-specific sur-
vival (DSS) rate and the recurrence-free survival (RFS)
rate. The follow-up time refers to the period between the
last treatment day and the end of follow-up period or
death from disease in DSS, or the detection of OPSCC
recurrence at the primary site, regional lymph nodes, or
at distant sites in RFS. In the RFS analysis, we censored
all events aside from recurrences. We considered a P-
value of less than 0.05 as statistically significant.
Results
Expressions of the markers
Bmi-1 expression was nuclear and present in 61% (123/
202) of the tumors. The cytoplasmic expression of
HESC5:3 was seen in 67% (136/202) of the tumors,
while the nuclear expression of HESC5:3 was only seen
in 3% (6/202) of the tumors. HES77 expression was
cytoplasmic and detected in 44% (88/202) of the tumors
(Figure 1 and Table 1).
Relationship between the markers and HPV status
and p16 immunoexpression
Bmi-1 was expressed in 50% (53/105) of HPV-positive
and in 54% (63/117) of p16-positive tumors; and it was
expressed in 72% (70/97) of HPV-negative and in 71%
(60/85) of p16-negative tumors. The expression of Bmi-
1 was lower in HPV- and p16-positive tumors than in
HPV- and p16-negative tumors (Table 2). Low Bmi-1
expression was associated with HPV positivity also in
our multivariable analysis, when the analysis was con-
trolled for other studied markers, smoking, T class, N
class, and age (Table 3).
Cytoplasmic HESC5:3 expression was found in 71%
(75/105) of HPV-positive and in 73% (85/117) of p16-
positive tumors and in 63% (61/97) of HPV-negative
and 60% (51/85) of p16-negative tumors.
Nuclear HESC5:3 expression was seen in 4% (4/105)
of HPV-positive tumors and 4% (5/117) of p16-positive
tumors and in 2% (2/97) of HPV-negative and 1% (1/
85) of p16-negative tumors.
The cytoplasmic expression of HESC5:3 was
observed more in HPV- and p16-positive than in
HPV- and p16-negative tumors, while there was no
correlation between the nuclear HESC5:3 expression
and HPV or p16 status (Table 2). In addition, multi-
variable analysis revealed that high cytoplasmic
HESC5:3 expression was associated with HPV posi-
tivity (Table 3).
HES77 was expressed in 50% (53/105) of HPV-posi-
tive and 48% (56/117) of p16-positive tumors and in
36% (35/97) of HPV-negative and 38% (32/85) of p16-
Table 3. Multivariable logistic regression analysis for variables
predicting HPV positivity in oropharyngeal squamous cell
carcinoma (n = 202).
Variables P OR 95% CI for OR
Lower Upper
Smoking
Never REF
Earlier 0.052 0.172 0.029 1.018
Currently \0.001 0.017 0.003 0.100
Bmi-1
0 REF
1–2 0.005 0.251 0.097 0.652
3–4 0.006 0.181 0.054 0.606
HESC5:3
0 REF
1–2 0.011 3.532 1.334 9.354
3 0.010 6.650 1.559 28.360
HES77
0 REF
1–2 0.151 1.922 0.787 4.692
3–4 0.183 2.582 0.639 10.445
cT
T1–2 REF
T3–4 0.543 0.773 0.337 1.773
cN
N0 REF
N+ 0.009 5.282 1.529 18.247
Age 0.093 0.962 0.920 1.006
HPV: human papillomavirus; OR: odds ratio (for HPV positivity); CI:
confidence interval; REF: reference category.
OR. 1 = a positive relation between the variable and HPV positivity;
OR\1 = a negative relation between the variable and HPV positivity;
age was analyzed as a continuous variable.
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negative tumors. The expression of HES77 was
observed more in HPV-positive than in HPV-negative
tumors, whereas no correlation was detected between
HES77 expression and p16 (Table 2). According to our
multivariable model, HES77 was, however, not inde-
pendently associated with HPV positivity (Table 3).
Correlations between markers and other
clinicopathological parameters and survival
HES77 expression was significantly associated with
smoking status. Among patients with HES77-negative
tumors, the relative proportion of smokers and ex-
smokers was higher than among those with HES77-
positive tumors (Table 4).
We found no significant relation between Bmi-1,
HESC5:3, and HES77 expressions and the patient’s age
(Bmi-1: p=0.165; HESC5:3-cytoplasm: p=0.060;
HESC5:3-nuclear: p=0.960; HES7: p=0.720). We
found no correlation between Bmi-1, HESC5:3, or
HES77 expression and tumor extension (T class), pres-
ence of neck metastasis (N class), stage (Table 5), or
survival (Figure 2).
Multivariable analysis revealed a negative relation-
ship between smoking and HPV positivity and a posi-
tive relationship between N class and HPV positivity
(Table 3).
Discussion
In this study, we examined the expressions of Bmi-1, a
well-known stem cell marker, and two recently discov-
ered stem cell markers HESC5:3 and HES77 in a series
of 202 oropharyngeal carcinomas. To our knowledge,
this is the first study to show a relationship of HESC5:3
and HES77 to HPV and p16ink expression in OPSCC.
In addition, we found that HPV-positive and p16-posi-
tive tumors expressed less Bmi-1.
HPV-positive HNSCC tumors have better prog-
nosis5,10 and better response to radiotherapy than nega-
tive tumors. HPV positivity promotes cells to become
CSCs and increases the formation of metastasis.21 The
detection of primary OPSCC, especially in the case of
HPV-positive tumors, is often preceded by the detec-
tion of neck metastasis.31 This agrees with our results,
showing higher expression of HESC5:3 and HES77 in
HPV-positive OPSCCs that tend to metastasize at an
Table 4. Expression of Bmi-1, HESC5:3, and HES77 and their association with smoking and alcohol abuse in oropharyngeal
squamous cell carcinoma (n = 202).
Variable Smoking Alcohol use
Never Ex-smoker Regularly All P No Previously Yes All P
Bmi-1
0 12 17 30 59 19 10 11 40
1 6 14 27 47 18 5 10 33
2 4 7 19 30 10 2 10 22
3 4 6 9 19 7 5 2 14
4 0 5 11 16 7 2 5 14
Total 26 49 96 171 0.192b 61 24 38 123 0.909b
Cytoplasmic HESC5:3
0 11 14 30 55 14 5 16 35
1 4 15 28 47 21 7 9 37
2 6 15 29 50 18 9 10 37
3 5 5 9 19 8 3 3 14
Total 26 49 96 171 0.878a 61 24 38 123 0.137a
Nuclear HESC5:3
0 25 48 93 166 57 24 38 119
1 0 0 2 2 2 0 0 2
2 0 1 0 1 1 0 0 1
3 1 0 1 2 1 0 0 1
Total 26 49 96 171 0.601b 61 24 38 123 0.114b
HES77
0 10 27 60 97 31 16 23 70
1 9 13 23 45 17 3 10 30
2 0 5 6 11 6 1 1 8
3 7 3 3 13 5 3 2 10
4 0 1 4 5 2 1 2 5
Total 26 49 96 171 0.036b 61 24 38 123 0.472b
aChi-squared test with asymptotic P-value.
bChi-squared test with exact P-value.
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early stage. In addition, in our cohort, we found a posi-
tive correlation between HPV positivity and regional
lymph node metastasis. We speculate that HESC5:3
and HES77 in CSCs, which are actively dividing, might
involve in the positive radiosensitive response of HPV-
positive OPSCCs.
In cervical carcinoma, no correlation between Bmi-1
and HPV infection has been detected.32 In contrast, in
penile carcinoma, the highest Bmi-1 expression was
found in HPV-negative tumors.33 These results mimic
our results showing that the expression of Bmi-1 was
lower in HPV-positive and p16-positive OPSCC.
Moreover, Bmi-1 is known to suppress p16ink expres-
sion. According to our results, HPV and p16-positivity
suppressed Bmi-1 expression, suggesting a bidirectional
pathway.
Tumors in older people are more often caused by
tobacco smoking and alcohol use than by HPV8 and
are more often both p16 and HPV negative.8,34
Similarly, in our cohort, most of HPV-negative tumors
were diagnosed among currently smoking patients.
However, we found no association between age and
HPV infection or p16 status.
In previous studies, a high Bmi-1 expression has
strongly associated with a poor prognosis in oropharyn-
geal carcinoma 19 and in tongue,35 cervical,32,36 and urin-
ary bladder cancer;37 but contradictory results have also
been reported.26 HPV-positive tumors are known to have
a better prognosis, and indeed, in our study, a higher
Bmi-1 expression was more commonly observed in HPV-
negative tumors, which are known to be more aggressive.
It may be that a high Bmi-1 expression reflects the aggres-
siveness of the tumor. However, no correlation between
its expression and patient survival was found.
HESC5:3 did not associate with prognosis in follicu-
lar thyroid cancer,27 while HES77 expression has been
linked to a poorer prognosis in rectal neuroendocrine
tumors.28 In our study, although HESC5:3 and HES77
are expressed more in HPV-positive tumors (which
have better prognosis) than HPV-negative tumors, we
found no correlation between the expression of HES77
or HESC5:3 and the prognosis in OPSCC.
Table 5. Expression of Bmi-1, HESC5:3, and HES77 and their association with clinicopathological factors in oropharyngeal
squamous cell carcinoma (n = 202).
Variable Tumor staging
Primary tumor (T) Regional lymph nodes (N) Stage
T1–2 T3–4 All P N0 N+ All P I–II III–IV All P
Bmi-1
0 39 40 79 15 64 79 9 70 79
1 32 19 51 9 42 51 9 42 51
2 18 13 31 4 27 31 3 28 31
3 16 7 23 7 16 23 5 18 23
4 9 9 18 4 14 18 4 14 18
Total 114 88 202 0.353a 39 163 202 0.503a 30 172 202 0.231b
Cytoplasmic HESC5:3
0 37 29 66 9 57 66 5 61 66
1 34 24 58 13 45 58 11 47 58
2 31 25 56 13 43 56 11 45 56
3 12 10 22 4 18 22 3 19 22
Total 114 88 202 0.867a 39 163 202 0.336a 30 172 202 0.173a
Nuclear HESC5:3
0 110 86 196 39 157 196 30 166 196
1 2 1 3 0 3 3 0 3 3
2 0 1 1 0 1 1 0 1 1
3 2 0 2 0 2 2 0 2 2
Total 114 88 202 0.565b 39 163 202 0.392b 30 172 202 0.523b
HES77
0 64 50 114 18 96 114 15 99 114
1 31 22 53 14 39 53 10 43 53
2 9 6 15 3 12 15 3 12 15
3 8 7 15 4 11 15 2 13 15
4 2 3 5 0 5 5 0 5 5
Total 114 88 202 0.732a 39 163 202 0.611b 30 172 202 1.000b
aChi-squared test with asymptotic P-value.
bChi-squared test with exact P-value.
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Conclusion
Our results show a lower Bmi-1 expression and a higher
HESC5:3 expression in HPV-positive tumors than in
HPV-negative tumors, while the relationship between
HES77 expression and HPV status was not, statisti-
cally, confirmed. Thus, HESC5:3, HES77, and Bmi-1,
may play a different role in HPV-positive and HPV-
negative tumors. Further studies are needed to verify
the roles of HESC5:3 and HES77 in stem cells.
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